Pancreatic Cancer Research

ResearcherUniversidad Complutense de MadridActive in the last 2 years

Andrés Muñoz

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5100979059, A5107841221, A5144192044. Sources: ClinicalTrials.gov.

Their work

Papers
7
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 trial · 2024: none · 2025: none · 2026: 2 papers

Papers 7

  1. Mainstream and fast-track genetic testing in pancreatic cancer patients and its impact on treatment: our experience in a tertiary hospital in Spain. Co-author DOI 10.1007/s10689-026-00595-8↗
  2. Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial. Co-author DOI 10.1038/s41591-026-04705-y↗
  3. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Tr… Co-author DOI 10.1158/1078-0432.ccr-21-0929↗
  4. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Co-author DOI 10.1038/s41591-020-0880-x↗
  5. Management and supportive treatment of frail patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.jgo.2018.06.005↗
  6. Management of hyperbilirubinaemia in pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2018.01.078↗
  7. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Co-author DOI 10.1007/s12094-016-1594-x↗

Trials 1

  1. Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer Principal investigator NCT05673811↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 6 shared papers, 1 shared trial, 2017–2026 · strength 0.83
  2. Manuel M. Hidalgo · 6 shared papers, 2017–2026 · strength 0.61
  3. Carmen Guillén‐Ponce · 3 shared papers, 1 shared trial, 2017–2026 · strength 0.58
  4. Mireya Cazorla · 1 shared paper, 1 shared trial, 2023–2026 · strength 0.43
  5. Vivek Sharma · 1 shared paper, 1 shared trial, 2023–2026 · strength 0.43
  6. Eva Martínez de Castro · 1 shared paper, 1 shared trial, 2023–2026 · strength 0.43
  7. Roberto Pazo-Cid · 2 shared papers, 2017–2026 · strength 0.26
  8. I. Marquez-Rodas · 1 shared paper, 2026 · strength 0.24
  9. M. Bringas Beranek · 1 shared paper, 2026 · strength 0.24
  10. Alfredo Carrato Mena · 3 shared papers, 2017–2019 · strength 0.22
  11. Roberto Pazo · 1 shared trial, 2023 · strength 0.22
  12. Rocío García · 1 shared trial, 2023 · strength 0.22
  13. Alana TH Nguyen · 1 shared trial, 2023 · strength 0.22
  14. Christopher Nevala-Plagemann · 1 shared trial, 2023 · strength 0.22
  15. Arjun Mittra · 1 shared trial, 2023 · strength 0.22
  16. Berta Laquente · 1 shared trial, 2023 · strength 0.22
  17. Miriam Lobo · 1 shared trial, 2023 · strength 0.22
  18. Inmaculada Gallego · 1 shared trial, 2023 · strength 0.22
  19. Edward Kim · 1 shared trial, 2023 · strength 0.22
  20. Alexander I. Spira · 1 shared trial, 2023 · strength 0.22
  21. Tara E Seery · 1 shared trial, 2023 · strength 0.22
  22. Luis Alfonso Rojas · 1 shared paper, 2026 · strength 0.21
  23. Rocio García‐Carbonero · 1 shared paper, 2026 · strength 0.21
  24. Edward Jae-Hoon Kim · 1 shared paper, 2026 · strength 0.21
  25. Chris Nevala-Plagemann · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.